A Prospective Pragmatic Clinical Trial Of China Early Invasive Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin
Phase of Trial: Phase IV
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Exemestane (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 09 Dec 2015 Planned End Date changed from 1 Mar 2019 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
- 09 Dec 2015 Planned primary completion date changed from 1 Mar 2019 to 1 Dec 2018 as reported by ClinicalTrials.gov record.